about
Limitations of current Parkinson's disease therapy.Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial.Persistent use of analgesic medications in mild-to-moderate Alzheimer's diseaseEmerging analgesic drugs for Parkinson's disease.Parkinson's patients can rely on perspective cues to perceive 3D space.Characterization of Burning Mouth Syndrome in Patients with Parkinson's Disease.Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study.Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia.Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.[Prevalence of diabetes in france and drug use: study based on the French pharmacovigilance database].Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family.[Parkinson disease and the noradrenaline system].Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease.Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498-499InsTC).Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population.Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms.Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson's disease.Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson's disease.[Other care in Parkinson's disease: Psychological, rehabilitation, therapeutic education and new technologies].Chronic pain and pain processing in Parkinson's disease.International validation of a behavioral scale in Parkinson's disease without dementia.Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease.Does ageing influence deep brain stimulation outcomes in Parkinson's disease?Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy.Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson's disease.Effect of subthalamic deep brain stimulation on pain in Parkinson's disease.Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.Cortical motor activation in akinetic schizophrenic patients: a pilot functional MRI study.Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.Clinical and economic analysis of spa therapy in Parkinson's disease.[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].Molecular Imaging of Opioid System in Idiopathic Parkinson's DiseaseSuggestive association between OPRM1 and impulse control disorders in Parkinson's disease.Quality of life predicts outcome of deep brain stimulation in early Parkinson disease
P50
Q34187123-9FC50B7E-3693-40A7-A3FA-CB2FAA4C86E3Q34278569-A815DA6B-56C6-49BE-B1DC-6D30EF78280FQ34716838-6D988A99-E2C4-4814-BA32-DDFD05C80472Q36148422-C11E6A75-E439-48F8-A5EB-A704B958F8C7Q37698700-89BB9786-DCAC-4A64-9B3A-6E7FD29679DFQ38005224-A2E459F5-AB7B-4E38-8AC0-1F83AF19E5C8Q38887764-ED9EF1C9-FFEB-47A3-ADE2-AC146190DA78Q39238190-B0A5DE9C-826B-4682-90F1-BBE6769547FDQ39293085-3E8E5000-19B5-4AB7-B9C0-7E6CEEA043DAQ40962558-9C6E7B69-8DC7-4ED9-B188-4809A7E71BFBQ41168222-CAAFF283-4F6C-4EF7-AB6B-493292439794Q43657399-45A14F2A-ACEF-407A-B0A1-95707893D1F5Q44022549-4C2DAF78-C1B5-452E-A96E-2527C932F322Q44125796-9181C89B-90B8-41AE-BB35-859C976DC288Q44531220-B0568A24-9A63-4C9D-8E23-A0E9FDD40A41Q45975097-0AF5524F-BE9F-4514-A85E-EFDF2C7501AEQ46190246-8995D5C9-7392-4E18-91A4-C1044991A27DQ46583182-8F843F62-1809-4AC8-A2BB-29A77DD9A0ACQ46632803-BB7D3359-EFFE-42D3-82D3-A6E81C663D0FQ47441283-86FD09DF-C621-4A9A-84F5-A25AA6C85278Q47678668-E8F44AD3-4922-4474-B802-B5BC4FEC02BBQ47693077-ADB47117-13E9-4774-929E-3E3164E96E0AQ48018688-CB62761F-7A09-42BC-9BB3-97B59931BC33Q48088853-47854781-9D34-4F54-BC98-9C1E20941F64Q48138841-CD340A99-E46F-4814-9405-7F21A1F86875Q48160799-B2876B25-CC4F-412F-ACB5-8FAE017CE53BQ48243848-B1FAE37D-0052-4F48-8FF7-198B509D4070Q48323361-289826B7-D334-48E3-BFA7-16F927E3639CQ48382343-C00F364F-B899-45BC-92CF-904CAF895ACAQ49920030-5520ED94-5DF7-4B50-A255-6F1466F76410Q52094514-64D7DCFE-E7E8-425A-9D24-9476791C6627Q53265340-4BDE3B87-186A-4C99-B90B-5BBD504206A2Q53302870-B39C9350-A8F2-4801-8EB2-EAD842AC6952Q53389523-CB58E7BA-933C-4ED7-B91E-95FFDE24A578Q54692964-4DF3C298-5B82-44B9-BE23-ECC5C9943695Q57498328-27B2D7DF-6751-4657-8047-C408D5BDFDC8Q59288075-A158D308-7330-4249-8A6F-904EC78CB53FQ64064367-5B6CC74F-4D4B-4172-BEC4-9197BA3FF060
P50
name
Christine Brefel-Courbon
@ast
Christine Brefel-Courbon
@en
Christine Brefel-Courbon
@nl
type
label
Christine Brefel-Courbon
@ast
Christine Brefel-Courbon
@en
Christine Brefel-Courbon
@nl
prefLabel
Christine Brefel-Courbon
@ast
Christine Brefel-Courbon
@en
Christine Brefel-Courbon
@nl
P214
P21
P214
P31
P735
P7859
viaf-296365919